MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb MAGNETISMM-3
Verified

What's the purpose of this trial?

The purpose of the study is to evaluate whether single-agent PF-06863135 can provide clinical benefit in participants with relapsed/refractory multiple myeloma. PF-06863135 is a bispecific antibody: binding of PF-06863135 to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

This trial is currently open and accepting patients.


What will happen during the trial?

Additional Trial Information

Phase 2

Enrollment: 150 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

Beverly Hills Cancer Center

Beverly Hills, CA

Open and Accepting

Florida

Baptist Health Medical Group Oncology, LLC

Miami, FL

Not Yet Accepting

Miami Cancer Institute Baptist Health South Florida

Miami, FL

Not Yet Accepting

Indiana

Franciscan Health

Indianapolis, IN

Recruitment on Hold

Louisiana

Ochsner Foundation Clinic

Jefferson, LA

Not Yet Accepting

Ohio

Pennsylvania

Fox Chase Cancer Center Temple Health

Philadelphia, PA

Not Yet Accepting

South Carolina

Prisma Health Boiling Springs

Boiling Springs, SC

Not Yet Accepting

Prisma Health Easley

Easley, SC

Not Yet Accepting

Prisma Health Greenville Memorial Hospital

Greenville, SC

Not Yet Accepting

Prisma Health Greer

Greer, SC

Not Yet Accepting

Prisma Health Seneca

Seneca, SC

Not Yet Accepting

Trial Links

Read the latest news and updates on this trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Pfizer to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors